3rd ADC Target Selection Summit

With the number of new clinical ADC targets reaching an all-time high, the 3rd ADC Target Selection Summit returns as the only industry-specific meeting spotlighting the latest developments in the field that will continue progressing first- and best-in-class ADCs through the clinic.

Providing a greater focus on identifying and validating novel targets, re-examining what makes a good target, and analyzing how novel linker-payload technologies are changing the target selection paradigm; this is your unique opportunity to delve into the use of proteomics to ensure you get the first step of drug development right.

With 100+ ADC enthusiasts set to be in the room including Iksuda Therapeutics, Merck and Co, Angiex, Ziel Bio, and Seagen; this is your chance to connect with peers working exclusively in biology, discovery, translational, target identification and validation.

Facilitating conversations on both the scientific and strategic elements of target selection for antibody-drug conjugates, this meeting will address all important discussions to inform your target selection and balance risk in your ADC pipeline for 2024 and beyond.

URLs:
Website: https://go.evvnt.com/1868494-0?pid=10018
Tickets: https://go.evvnt.com/1868494-2?pid=10018
Brochure: https://go.evvnt.com/1868494-3?pid=10018

Prices:
Drug Developer Pricing - Conference + Pre Conference Workshop Day: USD 4297.00,
Drug Developer Pricing - Conference Only: USD 2999.00,
Academic Pricing - Conference + Pre Conference Workshop Day: USD 3697.00,
Academic Pricing - Conference Only: USD 2599.00,
Solution Provider Pricing - Conference + Pre Conference Workshop Day: USD 5297.00,
Solution Provider Pricing - Conference Only: USD 3799.00

Speakers: Alexander Scholz, Senior Director, Atreca, Bill Mallet, Senior Director, Target Validation, Bolt Biotherapeutics, Carl Barrett, Vice-President, Translational Sciences, Former AstraZeneca, Daniel Calarese, Director of Innovation and Strategy, Sutro Biopharma, Dowdy Jackson, Executive Director, Research, Innovent Biologics, Elaine Hurt. Executive Director, Tumor Targeted Delivery, AstraZeneca, Hanspeter Gerber, Chief Scientific Officer and Co-Founder, Codeable Therapeutics, Jamie Rich, Director, Technology, Zymeworks, Jay Mettetal, Senior Director - Oncology Bioscience, AstraZeneca, Kimberly Kelly, Scientific Founder, President and Chief Operating Officer, Ziel Bio, Lesley Jenkinson, Principal Scientist, Cancer Research Horizons, Manoj Charati, Principal Scientist, Merck and Co., Martha Neagu, Medical Director, AbbVie, Mary Hu, Chief Executive Officer, Shanghai Miracogen, Natalie Grinshtein, Director - Cancer Target Discovery. Seagen, Randy Milby, Chief Executive Officer and Chairman, Hillstream BioPharma, Robert Lutz, Chief Scientific Officer, Iksuda Therapeutics, Shou-Ching, Jaminet Founder, Angiex, Stefan Ries, Chief Scientific Officer, R and D, DISCO Therapeutics, Steve Ludbrook, Director of Molecular Pharmacology, Bicycle Therapeutics, Zhinan Xia, Chief Scientific Officer, DynamiCure Biotechnology